These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18654416)

  • 1. Scientists worry about some risks more than the public.
    Scheufele DA; Corley EA; Dunwoody S; Shih TJ; Hillback E; Guston DH
    Nat Nanotechnol; 2007 Dec; 2(12):732-4. PubMed ID: 18654416
    [No Abstract]   [Full Text] [Related]  

  • 2. A little knowledge.
    Nat Nanotechnol; 2007 Dec; 2(12):731. PubMed ID: 18654415
    [No Abstract]   [Full Text] [Related]  

  • 3. Public attitudes to nanotechnology in Europe and the United States.
    Gaskell G; Ten Eyck T; Jackson J; Veltri G
    Nat Mater; 2004 Aug; 3(8):496. PubMed ID: 15286746
    [No Abstract]   [Full Text] [Related]  

  • 4. Risks and nanotechnology: the public is more concerned than experts and industry.
    Siegrist M; Wiek A; Helland A; Kastenholz H
    Nat Nanotechnol; 2007 Feb; 2(2):67. PubMed ID: 18654213
    [No Abstract]   [Full Text] [Related]  

  • 5. Indefinite particles.
    Toumey C
    Nat Nanotechnol; 2008 Jul; 3(7):372-3. PubMed ID: 18654552
    [No Abstract]   [Full Text] [Related]  

  • 6. Small advances.
    Goldston D
    Nature; 2007 Dec; 450(7173):1141. PubMed ID: 18097369
    [No Abstract]   [Full Text] [Related]  

  • 7. NANOtechnology: untold promise, unknown risk.
    Consum Rep; 2007 Jul; 72(7):40-5. PubMed ID: 17632953
    [No Abstract]   [Full Text] [Related]  

  • 8. Labeling of nanotechnology consumer products can influence risk and benefit perceptions.
    Siegrist M; Keller C
    Risk Anal; 2011 Nov; 31(11):1762-9. PubMed ID: 22084863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal cloning and the FDA--the risk assessment paradigm under public scrutiny.
    Rudenko L; Matheson JC; Sundlof SF
    Nat Biotechnol; 2007 Jan; 25(1):39-43. PubMed ID: 17211392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceived risks and perceived benefits of different nanotechnology foods and nanotechnology food packaging.
    Siegrist M; Stampfli N; Kastenholz H; Keller C
    Appetite; 2008 Sep; 51(2):283-90. PubMed ID: 18406006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not in my makeup: the need for enhanced premarket regulatory authority over cosmetics in light of increased usage of engineered nanoparticles.
    Johnson DR
    J Contemp Health Law Policy; 2009; 26(1):82-124. PubMed ID: 20112620
    [No Abstract]   [Full Text] [Related]  

  • 12. Review of health safety aspects of nanotechnologies in food production.
    Bouwmeester H; Dekkers S; Noordam MY; Hagens WI; Bulder AS; de Heer C; ten Voorde SE; Wijnhoven SW; Marvin HJ; Sips AJ
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):52-62. PubMed ID: 19027049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consumer reactions to food safety crises.
    Wansink B
    Adv Food Nutr Res; 2004; 48():103-50. PubMed ID: 15498694
    [No Abstract]   [Full Text] [Related]  

  • 14. What drives public acceptance of nanotechnology?
    Currall SC; King EB; Lane N; Madera J; Turner S
    Nat Nanotechnol; 2006 Dec; 1(3):153-5. PubMed ID: 18654170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of information about specific absorption rate (SAR) upon customers' purchase decisions and safety evaluation of mobile phones.
    Wiedemann PM; Schütz H; Clauberg M
    Bioelectromagnetics; 2008 Feb; 29(2):133-44. PubMed ID: 17935161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fairness and nanotechnology concern.
    McComas KA; Besley JC
    Risk Anal; 2011 Nov; 31(11):1749-61. PubMed ID: 21883336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vulnerability and social justice as factors in emergent U.S. nanotechnology risk perceptions.
    Conti J; Satterfield T; Harthorn BH
    Risk Anal; 2011 Nov; 31(11):1734-48. PubMed ID: 21453374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of vaccines.
    Bartlett BL; Tyring SK
    Dermatol Ther; 2009; 22(2):97-103. PubMed ID: 19335721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comments on public health concerns: facts, fiction and gaps in knowledge.
    Hoffman FA
    Thromb Res; 2005; 117(1-2):177-84; discussion 201-7. PubMed ID: 16182345
    [No Abstract]   [Full Text] [Related]  

  • 20. Comments on public health concerns: facts, fiction, and gaps in knowledge.
    Hoffman FA
    Thromb Res; 2005; 117(1-2):177-8; discussion 201-7. PubMed ID: 16183104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.